Press Releases

Accuray to Present at Cowen and Company 37th Annual Healthcare Conference on March 6, 2017 SUNNYVALE, Calif., February 21, 2017-- Accuray Incorporated (NASDAQ: ARAY), announced today that the Company will present at Cowen and Company’s 37th Annual Healthcare Conference in Boston on Monday, March 6, 2017. Read More »
CyberKnife® System Provides Long-term Disease Control for Prostate Cancer Patients SUNNYVALE, Calif., February 16, 2017 -- Accuray Incorporated (NASDAQ: ARAY) announced today data from a prospective, Phase II, 17-center study which showed that treatment with the CyberKnife® System for low- and intermediate-risk prostate cancer provides excellent long-term results. At five years, the disease-free survival rate for low-risk prostate cancer patients was 100 percent and for intermediate-risk patients was 88.5 percent. These results were maintained by patients followed for seven years. The study was presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in Orlando, Florida, February 16 – 18, 2017. Read More »
Accuray to Participate in the 2017 RBC Capital Markets Healthcare Conference on February 22, 2017 SUNNYVALE, Calif., February 13, 2017-- Accuray Incorporated (NASDAQ: ARAY), announced today that Kevin Waters, Senior Vice President and Chief Financial Officer, is scheduled to meet with investors one-on-one at the 2017 RBC Capital Markets Healthcare Conference in New York on Wednesday, February 22, 2017. Read More »
The Accuray Radixact™ System Receives Shonin Approval SUNNYVALE, Calif., February 8, 2017 – Accuray Incorporated (NASDAQ: ARAY) announced today that it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its Radixact™ Treatment Delivery System, Accuray Precision™ Treatment Planning System and iDMS™ Data Management System. Together, the treatment delivery system and software solutions enable clinicians to provide highly precise treatment, efficiently, for a wider range of cancer patients, including those undergoing retreatment. This new Radixact™ platform is now available in Japan, in certain markets in the European Union, and in the U.S. market. Read More »
Accuray Grows Second Quarter Gross Orders 17%; Backlog Up 16% YoY SUNNYVALE, Calif., January 31, 2017 – Accuray Incorporated (NASDAQ: ARAY) announced today financial results for the second fiscal quarter and six months ended December 31, 2016. Read More »
Miami Cancer Institute Treats First Cancer Patients with the Accuray Radixact™ System SUNNYVALE, Calif., January 26, 2017 – Accuray Incorporated (NASDAQ: ARAY) announced today that Miami Cancer Institute, a part of Baptist Health South Florida, is now treating patients using the new, uniquely "smart" Radixact™ Treatment Delivery System, fully integrated with the new Accuray Precision™ Treatment Planning System and iDMS™ Data Management System. Miami Cancer Institute selected the Radixact platform for its new, state-of-the-art treatment center because it offers leading edge, advanced treatment faster and expands access for more patients, while providing the foundation for anticipated clinical capabilities in the future Read More »
Accuray Continues to Set the Industry Standard for Customer Satisfaction SUNNYVALE, Calif., January 19, 2017 – Accuray Incorporated (Nasdaq: ARAY) announced today that its CyberKnife® and TomoTherapy® Systems continue to set the bar for excellence in customer satisfaction. Read More »
Accuray to Report Fiscal 2017 Second Quarter Financial Results on January 31, 2017

SUNNYVALE, CALIF., January 17, 2017—Accuray Incorporated (NASDAQ: ARAY) will report results for its fiscal second quarter ended December 31, 2016 on Tuesday, January 31, 2017 after the market close. Management will host a conference call to review the results at 1:30 p.m. PT/4:30 p.m. ET on the same day.

Read More »

Seiten